KRAS and pancreatic adenocarcinoma: However, PTPN2 expression levels are not significantly associated with survival in KRAS high expression patients or KRAS low expression patients with PAAD (p = 0.9121 and p = 0.2106, respectively) (Fig. 7, D and E).